Gene
INPP4B
INPP4B is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (2), Trial mentions (3), Target-disease associations (362), and 4 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention INPP4B. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
INPP4B has 3 trial mentions across 3 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 1 of 11,460 | 0.01% |
| 2022 | 0 of 8,285 | 0.00% | 1 of 13,598 | 0.01% |
| 2021 | 0 of 8,692 | 0.00% | 4 of 15,045 | 0.03% |
| 2020 | 0 of 7,640 | 0.00% | 4 of 14,459 | 0.03% |
| 2019 | 1 of 7,300 | 0.01% | 5 of 12,159 | 0.04% |
| 2018 | 0 of 6,927 | 0.00% | 2 of 11,854 | 0.02% |
| 2017 | 1 of 6,558 | 0.02% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| INPP4B oncogenic mutation | Pi3k Pathway Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| INPP4B deletion | Pi3k Pathway Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (3)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04192981 | Trial eligibility (AACT) |
| NCT02506556 | Trial eligibility (AACT) |
| NCT03206203 | Trial outcomes (AACT) |
Target-disease associations (362)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3C syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| Abnormal nasolacrimal system morphology | phenotype | GWAS credible sets |
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
| Achalasia | phenotype | Literature (Europe PMC) |
Showing 5 of 362 associations.
Vendor sourcing (16)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.2050G>A (p.V684I) alteration is located in exon 22 (coding exon 18) of the INPP4B gene. This alteration results from a G to A substitution at nucleotid... | View ClinVar record SCV003526621.2 |
| Genentech | Trial collaborator | Exploratory endpoint in a trialTrial endpoint | Status of p53, BRCA1/2, PIK3CA, PTEN, INPP4B and Other Mutations | View trial NCT03206203 |
| Genentech | Trial collaborator | Mentioned in trial textTrial free-text mention | INPP4B | View trial NCT03206203 |
| Greenwood Genetic Center | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Gene of Uncertain Significance | View ClinVar record SCV005874330.1 |
| Kazia Therapeutics Ltd | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically confirmed solid tumor malignancies harboring PIK3CA mutations which include mutations in any of the following genes: PIK3CA, PIK3CB, PIK3... | View trial NCT04192981 |
Showing 5 of 16 sourcing records.
Trial-cited literature (36)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. | Cancers | 2023 | 89 |
| Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | 57 |
| A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2021 | 42 |
| Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. | Genome medicine | 2021 | 18 |
| Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome. | Case reports in oncology | 2021 | 15 |
Showing 5 of 36 papers.
Literature-extracted relations (2)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Breast Neoplasms | Disease | associate |
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). | 2018 |
| Carcinoma, Intraductal, Noninfiltrating | Disease | associate |
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. | 2014 |
Organizations publishing (101)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Hospital | 3 | 2008 to 2017 |
| Dana-Farber Cancer Institute | Other | 3 | 2015 to 2020 |
| Harvard Medical School | Academic | 3 | 2015 to 2020 |
| Memorial Sloan Kettering Cancer Center | Hospital | 3 | 2012 to 2020 |
| Vanderbilt Health | Industry | 3 | 2011 to 2016 |
Showing 5 of 101 organizations.
Where INPP4B appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- respiratory or thoracic disease
359 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, protein variant mentions, and human sample screening reference.